<SEC-DOCUMENT>0001564590-19-035081.txt : 20190920
<SEC-HEADER>0001564590-19-035081.hdr.sgml : 20190920
<ACCEPTANCE-DATETIME>20190920090040
ACCESSION NUMBER:		0001564590-19-035081
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20190920
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190920
DATE AS OF CHANGE:		20190920

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		191102732

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>fgen-8k_20190920.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-09-20T11:35:59.0213633+00:00 -->
<!-- Version            : 3.6.7150.26138 -->
<!-- Package ID         : 8c1eb636ad7746f58535fffa3334c209 -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:fgen="http://www.fibrogen.com/20190920" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
fgen-8k_20190920.htm
</title>
</head>
<!-- NG Converter v5.0.19114.147 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0000921299_20190920_20190920">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0000921299_20190920_20190920">FIBROGEN INC</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0000921299_20190920_20190920">0000921299</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="fgen-20190920.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000921299_20190920_20190920">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-09-20</xbrli:startDate>
					<xbrli:endDate>2019-09-20</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:15pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0000921299_20190920_20190920">8-K</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0000921299_20190920_20190920" format="ixt:datemonthdayyearen">September 20, 2019</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:539.85pt;;">
<tr>
<td style="width:170.95pt;"></td>
<td style="width:4.5pt;"></td>
<td style="width:186.3pt;"></td>
<td style="width:5.35pt;"></td>
<td style="width:172.75pt;"></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000921299_20190920_20190920" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityFileNumber" contextRef="C_0000921299_20190920_20190920">001-36740</ix:nonNumeric></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000921299_20190920_20190920">77-0357827</ix:nonNumeric></p></td>
</tr>
<tr style="height:20.9pt;">
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of incorporation)</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0000921299_20190920_20190920">409 Illinois Street</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityAddressCityOrTown" contextRef="C_0000921299_20190920_20190920">San Francisco</ix:nonNumeric>, <ix:nonNumeric id="F_000011" name="dei:EntityAddressStateOrProvince" contextRef="C_0000921299_20190920_20190920">CA</ix:nonNumeric> <ix:nonNumeric id="F_000012" name="dei:EntityAddressPostalZipCode" contextRef="C_0000921299_20190920_20190920">94158</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices, including zip code)</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonNumeric id="F_000013" name="dei:CityAreaCode" contextRef="C_0000921299_20190920_20190920">415</ix:nonNumeric>) <ix:nonNumeric id="F_000014" name="dei:LocalPhoneNumber" contextRef="C_0000921299_20190920_20190920">978-1200</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report.)</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:12.4pt;">
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:WrittenCommunications" contextRef="C_0000921299_20190920_20190920" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:4%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:SolicitingMaterial" contextRef="C_0000921299_20190920_20190920" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:4%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:PreCommencementTenderOffer" contextRef="C_0000921299_20190920_20190920" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:4%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0000921299_20190920_20190920" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="bottom" style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:8pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:3.5%;width:90.83%;">
<tr>
<td style="width:28.83%;"></td>
<td style="width:34%;"></td>
<td style="width:28%;"></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style=" border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:Security12bTitle" contextRef="C_0000921299_20190920_20190920">Common Stock, $0.01 par value</ix:nonNumeric></p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:TradingSymbol" contextRef="C_0000921299_20190920_20190920">FGEN</ix:nonNumeric></p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:SecurityExchangeName" contextRef="C_0000921299_20190920_20190920" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:23.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000005" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000921299_20190920_20190920" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.<span style="margin-left:36pt;"></span><span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<br /></p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="border-top:Solid 0.75pt #7F0000;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;" id="part_1_2_1">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:424.3pt;;">
<tr>
<td style="width:43.2pt;"></td>
<td style="width:381.1pt;"></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.01</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.8pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Events</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 20, 2019, FibroGen, Inc., together with its collaboration partner Astellas Pharma Inc., announced that the Ministry of Health, Labour and Welfare in Japan has approved Evrenzo<span style="color:#4A442A;font-size:12pt;"><sup style="font-size:85%; vertical-align:top">&#174;</sup></span> (generic name: roxadustat) for the treatment of anemia associated with chronic kidney disease in dialysis patients.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A copy of such press release is attached as Exhibit&#160;99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:395.9pt;;">
<tr>
<td style="width:43.2pt;"></td>
<td style="width:352.7pt;"></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="part_1_2_2">Item&#160;9.01</p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:10.8pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financial Statements and Exhibits.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.63%;">
<tr>
<td style="width:0.41%;"></td>
<td style="width:6.84%;"></td>
<td style="width:6.67%;"></td>
<td style="width:44.39%;"></td>
<td style="width:41.32%;"></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
<td colspan="3" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibits</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr style="height:3.3pt;">
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.15pt;">
<td colspan="2" valign="bottom">
<p style="text-align:center;margin-top:18pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;No.</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="bottom">
<p style="border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:3.3pt;">
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:24.75pt;">
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fgen-ex991_6.htm"><span style="text-decoration:underline;">Press Release titled &#8220;Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients&#8221; dated September 20, 2019</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="border-top:Solid 0.75pt #7F0000;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="part_1_2_3">SIGNATURES</p>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:45.58%;"></td>
<td style="width:0.99%;"></td>
<td style="width:3.95%;"></td>
<td style="width:0.37%;"></td>
<td style="width:2.86%;"></td>
<td style="width:1.63%;"></td>
<td style="width:44.61%;"></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">F<span style="font-size:9pt;">IBRO</span>G<span style="font-size:9pt;">EN</span>, I<span style="font-size:9pt;">NC</span>.</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: September 20, 2019</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:3.3pt;">
<td valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:15.45pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:1pt;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Michael Lowenstein</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael Lowenstein</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Legal Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>fgen-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fgen-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.19114.147 -->
<body>

<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;text-align:right;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#3B3838;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr style="height:50.6pt;">
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#444142;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g34gh13buyut000001.jpg" title="" alt="" style="width:291px;height:81px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#444142;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g34gh13buyut000002.jpg" title="" alt="" style="width:228px;height:62px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#3B3838;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Press Release</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;color:#3B3838;font-size:12pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;color:#444142;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">SAN FRANCISCO and Tokyo, September 20, 2019<font style="font-weight:normal;">- FibroGen, Inc. (Nasdaq: FGEN, Interim CEO: James A. Schoeneck, &#8220;FibroGen&#8221;) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., &#8220;Astellas&#8221;) today announced that Japan&#8217;s Ministry of Health, Labour and Welfare (MHLW) approved Evrenzo<sup style="font-size:85%; vertical-align:top">&#174;</sup> (generic name: roxadustat; tradename Evrenzo<sup style="font-size:85%; vertical-align:top">&#174;</sup> in Japan) for the treatment of anemia associated with chronic kidney disease (CKD) in dialysis patients.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;color:#444142;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat is a first-in-class orally administered inhibitor of hypoxia-inducible factor (HIF) prolylhydroxylase that corrects anemia by a mechanism of action that is different from that of erythropoiesis-stimulating agents (ESAs). As a HIF-PH inhibitor, roxadustat activates a response that occurs naturally when the body responds to reduced oxygen levels in the blood. The response activated by roxadustat involves the regulation of multiple, complementary processes to promote erythropoiesis and increase the blood&#8217;s oxygen-carrying capacity.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;color:#444142;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Evrenzo<sup style="font-size:85%; vertical-align:top">&#174;</sup> is a valuable new treatment option for dialysis patients with CKD anemia,&#8221; said Bernhardt G. Zeiher, M.D., Chief Medical Officer, Astellas. &#8220;Astellas is committed to improving the health of people worldwide and expanding treatment options, especially within the dialysis community where there is high-unmet need. We are delighted to bring this important new treatment option to both patients suffering from, and healthcare professionals treating, this debilitating condition.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#3B3838;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CKD anemia can severely worsen the outcomes of kidney disease, increasing the rate of progression to renal failure<sup style="font-size:85%; vertical-align:top">1</sup><sup style="font-size:85%; vertical-align:top"></sup> and the likelihood of cardiovascular complications.<sup style="font-size:85%; vertical-align:top">2</sup><sup style="font-size:85%; vertical-align:top"></sup> It also significantly reduces patients&#8217; quality of life and their cognitive ability.<sup style="font-size:85%; vertical-align:top">3</sup><sup style="font-size:85%; vertical-align:top"></sup> Reaching and maintaining target hemoglobin levels can present challenges and roxadustat provides an alternative therapeutic option.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#3B3838;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We appreciate the commitment and focus of our partner Astellas as we work together to bring a new therapy to CKD anemia patients on dialysis in Japan,&#8221; said K. Peony Yu, M.D., Chief Medical Officer, FibroGen. &#8220;With this approval in Japan, NDA approval in China, and EU MAA and U.S. NDA preparations underway, we are another step closer to our goal of addressing the significant unmet medical need of patients living with anemia associated with CKD, worldwide.&#8221;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#444142;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;color:#444142;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-family:Times New Roman;color:#444142;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The approval is based on four Phase 3 studies conducted in CKD </font><font style="font-family:Times New Roman;color:#444142;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">anemia </font><font style="font-family:Times New Roman;color:#444142;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patients on dialysis in Japan.</font><sup style="font-size:85%; vertical-align:top">4</sup><font style="font-family:Times New Roman;color:#444142;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top"></sup></font><font style="font-family:Times New Roman;color:#444142;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">,</sup></font><sup style="font-size:85%; vertical-align:top">5</sup><font style="font-family:Times New Roman;color:#444142;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top"></sup></font><font style="font-family:Times New Roman;color:#444142;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">,</sup></font><sup style="font-size:85%; vertical-align:top">6</sup><font style="font-family:Times New Roman;color:#444142;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top"></sup></font><font style="font-family:Times New Roman;color:#444142;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">,</sup></font><sup style="font-size:85%; vertical-align:top">7</sup><font style="font-family:Times New Roman;color:#444142;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top"></sup></font><font style="color:#3B3838;"><sup style="font-size:85%; vertical-align:top"> </sup></font><font style="font-family:Times New Roman;color:#444142;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The studies demonstrated that roxadustat was effective at raising hemoglobin and that it was well-tolerated. </font><font style="color:#3B3838;">This marks the first approval for </font><font style="color:#3B3838;">roxadustat</font><font style="color:#3B3838;"> through the Astellas and FibroGen collaboration.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#3B3838;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Product Information</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:32.64%;"></td>
<td style="width:67.25%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;color:#3B3838;font-size:9pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">PRODUCT NAME</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;color:#3B3838;font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">Evrenzo<sup style="font-size:85%; vertical-align:top">&#174;</sup> Tablets<sup style="font-size:85%; vertical-align:top"> </sup>20mg </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;color:#3B3838;font-size:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">Evrenzo<sup style="font-size:85%; vertical-align:top">&#174;</sup> Tablets 50mg</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Evrenzo<sup style="font-size:85%; vertical-align:top">&#174;</sup> Tablets 100mg</p></td>
</tr>
<tr>
<td valign="top"  style=" border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;color:#3B3838;font-size:9pt;font-style:normal;text-transform:none;font-variant: normal;">GENERAL NAME</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roxadustat</p></td>
</tr>
<tr>
<td valign="top"  style=" border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;color:#3B3838;font-size:9pt;font-style:normal;text-transform:none;font-variant: normal;">INDICATIONS</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Renal anemia in patients on dialysis</p></td>
</tr>
<tr>
<td valign="top"  style=" border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;color:#3B3838;font-size:9pt;font-style:normal;text-transform:none;font-variant: normal;">DOSAGE AND ADMINISTRATION</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#3B3838;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Patients not on erythropoiesis-stimulating agent treatment. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For adults, the usual dosage is 50mg, the starting dose, as roxadustat orally administered three times weekly. The dosage thereafter should be adjusted according to the patient&#8217;s condition; however, the maximum dose should not exceed 3.0mg/kg. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#3B3838;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Patients switching from erythropoiesis-stimulating agents. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For adults, the usual dosage is 70 or 100mg, the starting dose, as roxadustat orally administered three times weekly. The dosage thereafter should be adjusted according to the patient&#8217;s condition; however, the maximum dose should not exceed 3.0mg/kg.</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;color:#3B3838;font-size:9pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">APPROVAL DATE</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#3B3838;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 20, 2019</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#3B3838;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About Chronic Kidney Disease (CKD) and Anemia<font style="font-weight:normal;"><br /></font><font style="color:#444142;font-weight:normal;">CKD is a progressive loss of kidney function caused by damage to the kidneys resulting from conditions such as hypertension, diabetes, or immune-regulated inflammatory conditions.<sup style="font-size:85%; vertical-align:top">8</sup><sup style="font-size:85%; vertical-align:top"></sup> Worldwide, more than 1 in 10 people are living with CKD.<sup style="font-size:85%; vertical-align:top">9</sup><sup style="font-size:85%; vertical-align:top"></sup> In Japan, specifically, the prevalence of CKD has increased significantly over time.<sup style="font-size:85%; vertical-align:top">10</sup><sup style="font-size:85%; vertical-align:top"></sup> </font><font style="font-weight:normal;">Although CKD can occur at any age, it becomes more common in aging populations, and the prevalence is increasing. CKD is a critical worldwide healthcare issue that represents a large and growing unmet medical need.</font><font style="color:#444142;font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#3B3838;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anemia is a common early complication of CKD,<sup style="font-size:85%; vertical-align:top">11</sup><sup style="font-size:85%; vertical-align:top"></sup> affecting approximately 20% of patients with CKD.<sup style="font-size:85%; vertical-align:top">12</sup><sup style="font-size:85%; vertical-align:top"></sup> It results from the failing kidneys&#8217; diminished ability to produce erythropoietin that stimulates red blood cell production from the bone marrow, and is associated with significant morbidity and mortality in dialysis and non-dialysis populations, increasing in both prevalence and severity as kidney disease worsens.<sup style="font-size:85%; vertical-align:top">13</sup><sup style="font-size:85%; vertical-align:top"></sup> CKD anemia increases the risk of adverse cardiovascular events, worsens renal outcomes and negatively impacts patients&#8217; quality of life.<sup style="font-size:85%; vertical-align:top">14</sup><sup style="font-size:85%; vertical-align:top"></sup><sup style="font-size:85%; vertical-align:top">,</sup><sup style="font-size:85%; vertical-align:top">15</sup><sup style="font-size:85%; vertical-align:top"></sup> In addition, CKD can be both a cause and a consequence of cardiovascular disease and is now a critical worldwide healthcare issue that represents a large and growing unmet medical need. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#3B3838;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>About Roxadustat <font style="font-weight:normal;"><br /></font><font style="color:#444142;font-weight:normal;">In addition to receiving approval from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, roxadustat is approved in China for treatment of anemia associated with CKD in both dialysis-dependent and non-dialysis-dependent CKD patients. U.S. NDA and EU MAA preparation is underway. </font><font style="font-weight:normal;">Roxadustat&#160;is also&#160;in&#160;Phase 3 </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#444142;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;color:#3B3838;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">clinical development in the U.S. and Europe and&#160;in&#160;Phase 2/3 development in China for anemia associated with&#160;</font><font style="font-weight:normal;">myelodysplastic</font><font style="font-weight:normal;">&#160;syndromes</font><font style="font-weight:normal;">.&#160;For information about roxadustat studies, please visit </font><font style="font-weight:normal;">www.</font><font style="font-weight:normal;">clinicaltrials.gov at: </font><font style="text-decoration:underline;font-weight:normal;">https://clinicaltrials.gov/ct2/results?term=roxadustat&amp;Search=Search</font><font style="font-weight:normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#3B3838;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas and FibroGen are collaborating on the development of roxadustat for the potential treatment of anemia in territories including Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa. FibroGen and AstraZeneca are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia in the U.S., China, and other markets. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;color:#444142;font-style:normal;text-transform:none;font-variant: normal;">About FibroGen <font style="font-weight:normal;"><br />FibroGen, Inc., headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People&#8217;s Republic of China, is a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company&#8217;s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase (HIF-PH) activity, completing worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), and is approved by the National Medical Products Administration (NMPA) in China, and by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS).</font> <font style="font-weight:normal;">Pamrevlumab, an anti-CTGF human monoclonal antibody, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#3B3838;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">About Astellas</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;color:#3B3838;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit <font style="text-decoration:underline;">https://www.astellas.com/en</font><font style="text-decoration:none;">.</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#3B3838;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">FibroGen Forward-looking Statements </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-size:10pt;font-family:Times New Roman;color:#444142;font-style:normal;text-transform:none;font-variant: normal;">This release contains forward-looking statements regarding FibroGen strategy, future plans and prospects, including statements regarding the development of the company&#8217;s product candidates, the potential safety and efficacy profile of our product candidates, and our clinical and regulatory plans, and those of our partners. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as &#8220;may,&#8221; &#8220;will&#8221;, &#8220;should,&#8221; &#8220;on track,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and our quarterly report on 10-Q for the fiscal quarter ended June 30, 2019 filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.<font style="color:#3B3838;"> </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#444142;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#3B3838;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="color:#3B3838;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Astellas </font><font style="color:#3B3838;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Cautionary Notes</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;color:#3B3838;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management&#8217;s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas&#8217; intellectual property rights by third parties.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:normal;color:#3B3838;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:center;text-indent:0%;color:#3B3838;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">###</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#3B3838;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Contacts for inquiries or additional information:</p>
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;text-indent:0%;color:#3B3838;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Karen L. Bergman </p>
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;text-indent:0%;color:#3B3838;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FibroGen, Inc.<br />Investor Relations and Corporate Communications<br />+1 (415) 978-1433<br /><font style="text-decoration:underline;">ir@fibrogen.com</font> </p>
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;text-indent:0%;color:#3B3838;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas Pharma Inc.<br />Corporate Communications<br />TEL: +81-3-3244-3201 FAX: +81-3-5201-7473</p>
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;text-indent:0%;font-weight:bold;color:#3B3838;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">References:</p>
<p style="margin-bottom:0pt;text-align:left;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">1</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Mohanram A, Zhang Z, Shahinfar S,ET AL. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. <font style="font-style:italic;">Kidney Int.</font> 2004 Sep;66(3):1131-8.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">2</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Weiner DE , Tighiouart H, Stark PC et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. <font style="font-style:italic;">Am J Kidney Dis</font>. 2004 Aug;44(2):198-206.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">3</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Eriksson D et al. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. <font style="font-style:italic;">BMC Nephrology</font>. 2016;17:97.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">4</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 1517-CL-0302: Announced on a press release issued on October 31, 2017. Available at: <font style="color:#444142;">https://www.astellas.com/jp/en/news?type=date&amp;tab=date&amp;year=2017&amp;month=10</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">5</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 1517-CL-0308: Announced on slide no. 29 of presentation material at Astellas FY2017 business announcement on April 26, 2018. Available at: <font style="color:#444142;">https://sw4503.swcms.net/en/ir-library/business-results/inframe/main/00/teaserItems1/00/linkList/02/link/4q2018_pre_en.pdf</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">6</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 1517-CL-0312: Announced on slide no. 29 of presentation material at Astellas FY2017 business announcement on April 26, 2018. Available at: <font style="text-decoration:underline;">https://sw4503.swcms.net/en/ir-library/business-results/inframe/main/00/teaserItems1/00/linkList/02/link/4q2018_pre_en.pdf</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">7</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 1517-CL-0307: Announced on a press release issued on May 31. Available at: <font style="text-decoration:underline;">https://www.astellas.com/jp/en/news/11951</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">8</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Ojo, A. Addressing the Global Burden of Chronic Kidney Disease Through Clinical and Translational Research. <font style="font-style:italic;">Transactions of the American Clinical and Climatological Association</font>. 2014, No. 125, p. 229-246. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">9</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The Global Kidney Health Atlas. International Society of Nephrology (ISN). Available at: <font style="text-decoration:underline;">https://www.kidneycareuk.org/news-and-campaigns/news/estimated-1-10-people-worldwide-have-chronic-kidney-disease/</font>. Last accessed August 2019.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">10</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Nagata M, Ninomiya T, Doi Y, Yonemoto K, Kubo M, Hata J, Tsuruya K, Iida M, Kiyohara Y. <font style="font-style:italic;">Nephrol Dial Transplan</font>t. 2010, Aug, vol. 25, no.8, 2557-2564.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">11</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="Background-color:#FFFFFF;">McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease.&#160;</font><font style="font-style:italic;Background-color:#FFFFFF;">Curr.Med.Res.Opin</font><font style="Background-color:#FFFFFF;">.&#160;2004;20:1501&#8211;1510.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">12</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Dmitrieva O, <font style="color:#444142;">De Lusignan</font> S, <font style="color:#444142;">Macdougall</font>, IC, et al. Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. <font style="font-style:italic;">BMC Nephrology.</font> 2013:25;14:24<font style="font-weight:bold;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">13</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> KDOQINational Kidney Foundation: KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47 [Suppl 3]: S11&#8211;S145, 2006.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">14</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Eriksson D et al. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. <font style="font-style:italic;">BMC Nephrology</font>. 2016;17:97.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">15</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#323031;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> KDOQINational Kidney Foundation: KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47 [Suppl 3]: S11&#8211;S145, 2006.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#444142;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g34gh13buyut000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g34gh13buyut000001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X01817AI9@  34T *@    @ #P#^  0
M   !      $   0    !   $]P$!  0    !   !2P$"  ,    #    P@$#
M  ,    !  4   $&  ,    !  (   $1  0   !O    R $5  ,    !  ,
M  $6  0    !     P$7  0   !O   "A $:  4    !   $0 $;  4    !
M   $2 $<  ,    !  $   $H  ,    !  (   $]  ,    !  (
M"  (  @    (    NP   6X   (A   "U    X<   0Z   $[0  !:    93
M   '!@  ![D   BA   )?   "E\   LV   ,&0  #/X   W?   .RP  #^0
M !$S   2Q   %%8  !88   7T0  &<<  !O3   =[   ("@  "*D   DN
M)Z\  "LE   NT@  ,B8  #5U   XN0  ._T  #_#  !$#@  2,   $WK  !1
M<   5)4  %>Y  !<,@  83,  &6E  !J<P  ;U0  '.A  !WZ0  ?80  (,G
M  "(80  C3,  ))/  "7;@  G%T  *#-  "EB0  J@<  *X^  "RC   MK8
M +KJ  "_'@  P[8  ,G$  #/U0  U;D  -L.  #?-   XUD  .>S  #K[
M\)H  /6B  #Y#P  ^R@  /US  #_PP ! =P  0/A  $%]0 !!Y$  0E8  $+
M$@ !#*<  0XC  $//@ !$$<  1$E  $2!@ !$NH  1.^  $4I0 !%7L  19D
M  $7*0 !%]P  1B/  $90@ !&?4  1JH  $;6P !' X  1S!  $==  !'B<
M  "S    LP   +,   "S    LP   +,   "S    LP   +,   "S    LP
M .@   #;    XP   -<   #C    Y0   .$   #L   !&0   4\   &1   !
MD@   <(   &Y   !]@   @P   (9   "/    GP   (4   "]P   W8   .M
M   #5    T\   -$   #1    \8   1+   $L@  !2L   .%   #)0   R0
M  1Y   % 0  !'(   3.   $X0  !$T   1(   %FP  !:,   4Z   $T@
M!1P   4?   $[P  !'    2\   $?@  !#<   1.   $*@  !#0   0T   $
MF   !@X   81   %Y   !54   0F   $)0  !%H   0Y   $K@  !0@   -M
M   "&0   DL   )0   "&0   @4   (4   !G    <<   &Z   !E0   7P
M  $;   !"0   -X   #A    Y    -0   #G    U@   .D   #%    LP
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHK+UW5M.TK3R=2NFMXY\Q*R ELD=1@$\>M-*[LB9S4(N4G9&7JUGX
M@NO%.G76F7Z+ID1 GC$F!P?GW+_%D<#T/IUKJ*YWPEX73PS:W"I?-=?:&#YV
M[5  XP,GGGK]/2NBJIM7LC'#QDDYR5G+5J][>@4445!T!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#IVF012#I*1OD_[Z;)_#-*T8L&G)6.)TSQ'XXUG2[.WT70H[2%84C-]>MPW
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M8SON>D4445B:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !4<[2I;RM!&LDP0F-&;:&;'
M)P<#/?%244 8_ASQ!#X@L7D\IK>\@<Q75JY^:&0=0?4>A[_G6Q7)^)-+N[#4
M%\4:'#OOH4VWELO'VR$=O]\=CUXQSP*W])U2TUK3(-0LI-\$R[E/<>H/H0>#
M5-=4)/H7:*R+C5=21V6V\/W<P5B S30H&QW'SYQ^%,%[XBE7*:/9P_\ 7:^)
M/_CJ'^='*S-UHWM9_<_\CE/&X_L'QQX=\3#Y8&?['=,<!0IS@GWPSG_@ KT6
MN$\::1X@UOPK>PW2Z6J1)YZK")'?<G/RDX&2,CIWJ3PG<ZYXC\*V-ZFNQ0$I
MY;A+-6<,IVG<2Q&3C/0=>E6U>*U)51[J+_#]6=O6),=_C6S3_GE83/\ ]]/&
M/Z&G)H^I%"L_B*^?/_/.&%/_ &0UBP^'0_BZX235=5D$=E&V\W95OF=^,KCY
M?EZ4HI:ZF=6<WRI1ZK=KUZ7.SKS!O^*W^(VW[^EZ=VZJP4_B#N;\U'M6IXXL
M],TCP]).WVN2ZE(B@,M[,_S'J<%\< $^F<5Q>GZIX=TC0TA6P36O$-R<I L9
MD2,G&U3C@\<D#)R2#BM*<;1YD<N)E.M6C0LK+5Z_<MCM_&D'A6SM@]WIT<VH
M3';;P6IV2RN?4CMZL<X]^E<//X:AT/38-1NO$VGVFI*0X@1BQC.>S)EB0,=%
MQ[]ZDT?X?>*=92:2_P#LNEP73!WWP*90.H"(/]6/8%3ZYKNM%^&/AO2-LDML
M=0N!UDN\.O3GY/N_F"?>GSJ"M<UG@X5G><$O-;_H</IWQ-\01VTFUX+Q5X$L
MT)^7TY7;G\:@M+]_%ER\?BKQ5=6MN6P+:"+9&X]R.!@_W@?K7KW_  CNAXQ_
M8VG?^ J?X55O_!GA_4(?+?2X(B,[7MU$3 ^ORXS^.:7M*?:QG'#8RG\$[KL]
M?Q.37PI:>&;F+7_#%M!JMHB@3VS;99,#_EI"_9O;O^5=G;W6E>+O#\AA=;BQ
MNHS'(.A7(Y!]&'^!KA-4^%MS;MY^CWBS;3D0W  ;Z9Z'\0!7(WL=[HNJV[W^
MD^2T9Q+!N>)+@#@D,IX/NIQTXZY?(I[/4F6.JTG:K3Y?.^GX)G??#F\GTN[U
M+P;J#YN-.<O;L1CS(B>H_,'K_'[5Z#7C/B5=(%MI_BOPY/.LEHZK>P?:G$RQ
MMQU+%AR2N1Q\WM7H-EH,%Y;07UGX@ULPSQK)&?MFX%2,CA@:SG%;L[859-)Q
M2:\F7/#!4:7-"O AO+F,?A,Y_K6S7':+I6HYU6&VUVZ@\J_D!S#$^XD*VXY7
MJ=W;BM9-/\01#C7X9O\ KM8#_P!E84I)7W)H5)*FER/3TZ?,YWXI:@T>D6>F
MQ%O,NYMS!3U5>Q'NQ4_A78:18+I>CV=BN/W$2H2.YQR?Q.37F=VNK:]\2(K?
M?:7$VG8.X*R1?(=W(R3]X[37?BX\2(/GTW39?^N=XZ_SCJYJT5$YL-54Z]2L
MT^RTOMOMYFU16&-6UM7Q+X;E(_O17D3?S(HE\1O;L%FT'60?]B!91_XXQK+E
M9W>WAN[KY/\ R-RN;\4:[<VC0:/HX676[X$0J?NPIWE?T YQZGUP15OQ'XA@
M\/Z<LS1M/=3L(K2U0?//(>B@>GJ?ZX!K^%_#\FF+/J6IN)];OCONINH0=HT]
M%7I[X]A@2MJS5]D7/#^A6_A_2UM(G::5F,EQ</\ ?GD/WG;ZUJT45+=QA111
M0 5F>)/^17U?_KRF_P#0#6G69XD_Y%?5_P#KRF_] --;@SY9HHHKO.4**U/#
M44<_BK1X9HTDBDOH5='7*L"X!!!ZBOH[_A%/#G_0 TO_ , X_P#"LYU%$N,>
M8^7:*^HO^$4\.?\ 0 TO_P  X_\ "C_A%/#G_0 TO_P#C_PJ/;KL5[-GR[17
MU%_PBGAS_H :7_X!Q_X4?\(IX<_Z &E_^ <?^%'MUV#V;/EVBOJ+_A%/#G_0
M TO_ , X_P#"C_A%/#G_ $ -+_\  ./_  H]NNP>S9\NU8L/^0E:_P#79/YB
MOIK_ (13PY_T -+_ / ./_"E7PMX>1@RZ#IBL#D$6D>0?RH]NNP>S9K5YY\7
M]%DU#PQ#?PQEY+"4L^.T;##''L0I^@->ATUT22-HY%5T8$,K#((/8USQ?*[F
MC5U8^2**]?\ $?P<\VY:XT"ZCB1SDVUP3A?]U@#Q[$?C6!:?!_Q)/-MN'L[:
M,'EVEW<>P _GBNQ5(M;F'(SG_!&D2ZSXPTZWC3<D<RS3$C@1H03GZ]/J17TS
M7/>$_!^G^$K)HK7=+<2X\ZX<?,^.P'8>W\ZZ&N:I/F>AM"-D%?/7Q5_Y'^\_
MZYQ?^@"OH6OGKXJ_\C_>?]<XO_0!54/B%4V.+HHHKJ,#ZU@_X]X_]P?RJ2HX
M/^/>/_<'\JDKSSJ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSGXD^/CHD3:/I<H_M&
M1?WLJGF!3Z?[1'Y#GTKI/&OB>/PKX?EN\JUW)^[MHS_$Y[GV'4_EW%?-EQ<3
M75S)<7$C232L7=V.2S'DDUM2IWU9G.5M$,9BS%F)+$Y)/>DHHKJ,0I0"Q  )
M)X %;/AGPOJ/BK4?LMC& B8,T[_<B'N?4]AU/T!(]X\,>!-&\+QJ\$(N+W'S
M74PRV?\ 9_NCD]/Q)K.=11+C%L\8TGX<>*-6".FG&VA8_P"LNF\L#WVGYL?0
M5TEK\%-5?/VO5;.+T\I6D_F%KVJBL'6D:*FCQ>Y^"FI*O^BZO:2MZ2QM&/TW
M5@ZG\+?%.FJSK:1WD:C):UDW?^.G#'\!7T-10JT@]FCY)FAEMYFAGB>*5#AD
M=2K*?<&F5]/>(O"FD>)[7RM0M@9 /W=Q'\LB?0^G/0Y'M7@OBWP7J/A*[ G'
MG6<C8AN4'RM[$?PM[?EFMX5%+0SE!HYNCH<BBE +,%4$DG  [UH0>X?#/QXV
MM0KHVJ2[M0B7]S*QYG0=CZL!^8Y[$UZ17E?P\^&S63P:WK<96Y4B2WM3P8SV
M9_\ :]NW?G@>J5Q5.7F]TZ(WMJ%%%%04%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<5J
M,,G@K6)-:M$9M#O'SJ-N@SY#G_ELH]/[P'Z\8[6FR1I-$\4J*\;J596&0P/4
M$>E-.PFA(I8[B%)H762*10R.IR&!Y!!]*?7$6<K>!-7CTJY9CX>O9"+*=B3]
MDD//E,?[I[$_XD=O0U8$PKSKP!_Q(?%7B+PJYQ''+]JM5SGY#COZ[3'^M>B$
M@#). .IKQWQMXMT[3O'FFZUHMS%>W5M"T-RB,?+88^4;AP?OGIG&T5<$W="D
M[:GL+NL:,[L%11EF8X 'J:\VN_B!!;^*=3BT6SDUF[FCAB@%ORGR[BQ)&<@%
M^PQQU%2+X0\2^+G6?Q=J1M;3.5TVS( '^\>1^>X\]144VIZ3\/GUJUTVW1;B
M::..U@!)QB%6+L3S@%C]2<>I%0BMMV85YJ-I2T2_R9R6I3^)_%FM"PNT22_1
MVC2"+ CM_P"]R,\#'))/3'I7JWA'P=8>$[ 1PJ);QQ^_N6'S.?0>B^U9/PST
M@V^CRZK.";B]<[6;D[ ?SY.3[X%=S15GKR+9&. IOD=:?Q3U^73\ HHHK$[P
MHHHH *AN;6WO(&@NH(YHFZI(H8'\#4U% FDU9GF?B_X=11V<E]H,+ET!,EGN
MW;U[[,\Y]N_;T/.^$OB#<:':K8>2EU8Q9(C^Z\8)YP?3)[COC(KVZO,/'&F0
M^%/$=AXPLK?]S)-Y6HPJ,K(&!R<=,D9SGC.T]2:Z(5.9<LM3@J8&,7ST'R/R
MV^XZ#PEXBT[5-2U4PS"-KFX66*&4A7(\M0>,\\J>E=1>74=C8W%W+GRX(VD;
M'7 &37FP\)Z/XIU34)](N5MX/)@GMVA7,9WAMP*\$<KTXP<\5F>(+CQ9H.ER
M:1JLZW%G<C;'.6WDX(8X;[WM\W;I0Z<92T9SK&5</2?M8W6NJVO=[]M3H/AC
M:R7+ZIKEQAIKB7RP^,'/WG_ DK^5>AUQ/@'7=%&AVFEQ70CO$!WQRC878G)V
M]FZ\=\#H*[:LZM^=W.O+U%8>*B[]_5[A5/5=4M-%TR?4+Z41V\*[F/<^@'J3
MT%69IH[>&2::18XHU+.[' 4#DDGTKC-.AE\:ZO%K=XK)H=HY.G6S#'GN.//<
M>G]T'].\I=6=C99\-Z9>ZEJ!\4:[#Y=Y(I6RM&Y^QPG_ -G8=3U[<=!UM%%)
MNX)6"BBBD,**** "LSQ)_P BOJ__ %Y3?^@&M.LSQ)_R*^K_ /7E-_Z ::W!
MGRS1117><IK^%/\ D<-$_P"O^#_T8M?45?+OA3_D<-$_Z_X/_1BU]15S5]T;
M4]@HHHK T"BBB@ HHHH **** "BBLSQ%=SV'AK5+NV?9/!:2R1O@':P4D'!X
MZT+4#3HKYT_X6?XQ_P"@Q_Y+0_\ Q%'_  L_QC_T&/\ R6A_^(K;V$C/VB/H
MNBO*_ACXPU[Q#K]U;:K??:(8[4R*ODHF&W*,Y50>A->J5G*+B[,M.ZN%?/7Q
M5_Y'^\_ZYQ?^@"OH6OGKXJ_\C_>?]<XO_0!6E#XB:FQQ=%%%=1@?6L'_ ![Q
M_P"X/Y5)4<'_ ![Q_P"X/Y5ROB?XB:+X:9[=G-Y?+UMX#]T_[3=%^G)]JX$F
MW9'2VEN==17@.K?%GQ)J#,MI)%I\)R L*!FQ[LV>?<8KDKO6=4U  7NI7ER!
MT$T[/C\S6JH/J0ZB/JNBODJ.XGA</%-(C#HRL016U9^-?$UA*)(-<O20,!99
M3*N/]U\C]*;H/HP]H?3=%>*:-\9=1MV2/6+**ZCX!EA_=R?7'W3].*]2T#Q5
MI'B:W\S3;H.ZC+PO\LB?5?QZC(]ZSE3E'<I23-FBBBH*"BBL_7;R73O#VI7L
M&WSK>UEE3<,C<JDC/XBA :%%>!_\+>\4>ME_WX_^O1_PM[Q1ZV7_ 'X_^O6O
ML9$>T1[Y17$?#?Q?>>*K"^.H>7]JMI5_U:;1L8<?CE6K1\7>-].\)6ZB?,][
M(,Q6J-@D?WF/\*^_Y X.(Y7?E*YE:YTU%?.>L_$GQ-J\C8OWLH<Y6*T)CQ_P
M(?,?SQ[5R\US/<2-)/-)+(QR6=RQ/XFM50?5D.HCZTHKY*BGF@D62*5XW4Y#
M(Q!'XUUOAOQMXP34[>RLM0FO9+B4*L-V?-#$\=3R!]"*'0?1@JA]$44U-XC4
M2%2^!N*C )]A3JP- HKFO$?CO0_#.8KJX,UV/^7:#YG'U[+U[GZ9KS+5OC'K
M=V633;:WL(ST8CS9!^)^7]*N-.4MB7)(]RHKYCNO&OB:[F,LNNWZL>T4QC7_
M +Y7 _2J9\0:T7WG5[\MZ_:7S_.M/8/N3[1'U117S%;^,O$MM,LL>NZ@67H)
M+AG7_OEB0?RKIM*^,'B"S95OX[?4(\_,67RW/T*\?^.TG1ET!5$>[T5R7AOX
MBZ%XB9(%F-G>MT@N,#<>/NMT;D].OM76UDTUN6FGL%%%%(8445A>,M8.A>$M
M0OT;;,L>R$CJ';Y5/X$Y_"FE=V!Z'BGQ*\1'7O%4T<3YL[(F"$ \$@_,WXGO
MZ 5QU%%=R5E8YF[NX5I:#HEUXAUFWTVT'[R5OF<CA%'5C[ ?X5FU[K\)/#BZ
M;H#:O.G^E7_W,CE8@>/S//N-M3.7*KCBKL[+0M"L?#NE1:?81[8DY9C]Z1N[
M,>Y/_P!;I6E117$W<Z HHHH **** "JNHZ=::MI\UC?0K-;S+M=&_F/0CUJU
M10!\V>*?!E_X>\1+IL44MS'<-_H;JN3*/3C^(=#^?>O4O ?PX@T!(]2U5$FU
M0\JG5+?Z>K>_;MZGOFBC>1)&16=,[&(Y7/7'I3ZUE5;5B%!)W"BBBLBPHHHH
M ***QO$'BK2/#-OYNI705V'R0)\TC_1?3CJ<#WII-[ ;-%>(ZW\8]5NF:/1[
M:*RBZ"60>9)]>?E'TP?K7$ZAXFUS5=XOM6O)D<Y:,RD)G_=' _ 5JJ,GN9NH
MCZADFBA&9940?[3 4V.Y@F.(IXW/^RX-?)?7K15>P\Q>T\CZYHKY3LM8U/3=
MWV'4;NUW=1#,R9^N#78Z1\6_$5@ZK?&'48<\B10CX]F7^H-2Z#Z#51=3WNBN
M6\,>/M%\3[88)3;WN.;:? 8\<[3T8=??CH*ZFLFFM&6G<****0PHK%\6ZC<Z
M3X5U&_M&"W$$6Y&*@@'([&O%O^%K^+/^?R'_ ,!T_P *N--R5T2Y);GT'17S
MY_PM?Q9_S^0_^ Z?X5Z[X"URY\0^$[>^O75[K>Z2,JA02&..![$4Y4W%78*:
M9TU%17%Q!:6[SW,T<,*#+R2,%51[DUYGX@^,EG;,T.A6OVMA_P O$X*1_@OW
MC^.*F,7+8;:6YZC17SCJ'Q(\5ZAO5M4>"-CD);((]OT8#=^M9?\ PE?B/_H/
MZK_X&2?XUK[!D>T1]145\WV'Q&\5Z>%5-6DF13DK<*)-WL2PW?K7=:#\9H97
M2'7K+R,G!N+;+*/JAY ^A/TJ71DAJ:9ZM14%G>VNHVD=U9W$<]O(,K)&V0:G
MK(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** .:O/%\=IXNM] -E*QEV@S ]"PXP,<CU.?7TKI::8T,BR%%+J
M" Q'(!Z\URNG^'IO#VL:SKTU]+=13)))]G1/F/.[UP2 ,#Z]JOW6NQS7JTY:
M^\F_2R_4ZRBN4T/Q_H^L,(9'-E<DX$<Y&UOHW3\#@UU=*47%V9I2K4ZL>:F[
MH***YWQ'XUT7PRA6[N/,NB/EM8?FD/U'1?QQ[9I)-Z(U;L;&I:=:ZMIT]A>Q
M"6WF7:ZG^8]".H->=P>/'\*-<>'KQ7UF\MG$=E):N&,RGHDF,E7'0\$^W<R?
M9_&?CL9NF/A_17_Y9+GSI5/8]#^>T<]#6T/AMH$&BM96<+070(>*_P YG20<
MJP;MSV&!_.M%RQTD0[O5&,/#OBWQJ1)XDO3I6EMR-/M>'8?[7_V6>?X16GK_
M ($TJ/P-J&FZ381Q3"/SHV"[I'=/F W'DD\CVW5I>&-=N;MYM'UD)%K=D/WJ
MC@3IVE3U![^A].E:>MZU9Z!I<E_>N0B_*B*,M(YZ*H[D_P#U^E)RE>P[*QRF
MC^.84\ :;>,#=:G(/LD5JC9DGF7Y?RZ,3VW>X%<)J%O=:AK/V"Z\N37+F]V7
M,P!VCA0JCT527S[ >@K:^'EE%I7C[4+74]-CM;Z:#[3:*6R(%;ED7WPP&>VQ
MAZU=\$VR:SX\U36E!,$,DCQ$^KDA?_'=U;1M%MH\S'J57V=%?:?X+<]*M+:*
MRLX;6$8BA01H/8# J:BBN4]1))604444#"BBB@ HHHH *S?$&D1Z]H%[IDF
M+B(JK'HK=5/X$ _A6E10G8#PWP!J]UX;DO)FLY#96[+%JJXR\)W,%D ZX&"&
M'N3].D\1S1>*?'^DZ9 ZS6<2J[$<JP8>8Q!'4% M%Q-:^%/BU<+<&-=-UNU+
MRJWW%?GDC'.2I_[^5B^"K^WT;6VU:XLC!I,[M:K< _N[9V(90<\XQQGMGFNI
M:WGY'E8F-W##K[4KOT6K.[USX>Z/JVZ6W3[#<G^.%?D)]TZ?EBN=%SXR\$_\
M?*?VEIB=6R7"C_>^\O'KQ7I]<=KVHW/B#5)/"VC2-&% .IWJ=((S_P LU/\
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M^O&;_P! -..XGL?+]%%%=YS'I/P7_P"1IOO^O(_^AI7N%>'_  7_ .1IOO\
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MA?W=Q&O19!UQ['@CZX[5RU:?+JC:$KZ,Z"L?Q7_R)VM_]>$__HMJV*Q_%?\
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M\_Y^Y_\ OX:/M]Y_S]S_ /?PU7HH L?;[S_G[G_[^&C[?>?\_<__ '\-5Z*
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MP0:^:O[<U?\ Z"M]_P"!#_XU])^*_P#D3M;_ .O"?_T6U?+M=-!:,RJ;E_\
MMS5_^@K??^!#_P"-']N:O_T%;[_P(?\ QJA16UD9W+_]N:O_ -!6^_\  A_\
M:/[<U?\ Z"M]_P"!#_XU0HHL@N:<.N:N9XP=4O?O#_EX?U^M?4U?)4/^OC_W
MA_.OK6L*_0TI]0KY\^*.NMK'B^:W1\VUA^X0 \;OXS]<\?\  17O6H7B:=IE
MU?2 F.VA>9L>B@D_RKY2EEDGFDFE8O)(Q9V/4D\DTJ"UN.H]+#***Z3P)IUK
MJ/B^R2^DB2TA)GE,KA5(7D#GKEL#'IFNANRN9+4]/^''@&'2+.'6-3@#ZE*
M\2./^/=3TX_OGOZ=/7/HU4?[:TK_ *"=E_W_ %_QH_MK2O\ H)V7_?\ 7_&N
M*3<G=G0DDK%ZBJ/]M:5_T$[+_O\ K_C1_;6E?]!.R_[_ *_XTK,=R]6%XJ\+
MV7BK27M+E0LZ@FWG ^:)O\#W'?ZX(O\ ]M:5_P!!.R_[_K_C1_;6E?\ 03LO
M^_Z_XT*Z=T+1GRY?6<^G7]Q97*;)X)#'(OH0<&J]=U\6$LV\8+=V<T<RW-LC
MR-'('&\97MT^55KA:[HNZN<[5F=Y\)M8;3O&"V;,1#?QF(C/&\#<I_0C_@5>
M^U\HZ7>G3=6L[]5W&VG28+Z[6!Q^E?5U<U=:W-:;TL<WX_\ ^1#UC_KA_45\
MU5]*^/\ _D0]8_ZX?U%?-5:4/A)J;A116UX2T3_A(?%%CIK9$4C[I2.R*-S<
M]B0,#W(K5NRN0=Q\./AU'J,4>MZW%NM2<VULW_+7_;;_ &?0=_IU]F1%C141
M0J*,*JC  ]*2.-(8DBC14C10JJHP !T IU<4YN3NSHBDD%%%%2,P/%/A+3O%
M>GM!=H$N%'[BY4?/&?ZCU'\CS7SEJVEW6BZK<:=>(%N('VMCH>X(]B,$?6OJ
MRO)/C3HR>5I^M1J V[[+*?7@LO\ )OTK:C-I\IG..ESR&E!*D$$@CD$4E%=1
MB?4/A;5O[<\+Z?J).9)H1YAQ_&/E;_QX&MBO.O@W>&;PE<6S2;FM[M@J_P!U
M&52/UW5Z+7#-6DT=,7=!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y;7? .CZSNECC^Q71Y\V
M$<$_[2]#^&#[UYM--K1LKFQ^TW.K>'[.Y5+AH2WER!<$IOQN"]CC@=NQ/H6O
MZC=:[JC>%M%D9,*#J=ZO2WC/\"_[;?H/QQT^G:?:Z5I\%C90K%;P+M1%[?XD
MGDGN36T:CBM=3AJX*$Y<]-\LNZ_5=3G_  [XUT/5(H;6)EL9E 1+:3"CT 4]
M#Z <'VKJ:Y;7? 6CZSNE2/['='GS8!@$_P"TO0_H?>N/U'_A+O!5C+ ]T+G3
M9%,,<N[=Y>00,9^92!SCI]:.2,_A9F\37PZ_?QNNZ_5%.RO+J3Q?J7BG3[!+
MFTLIS)-''PQB;<NY1W; +'\:LZ5KUG8?%>6ZL9%;2-;*1AT^Z92B-G'][>V#
MGH7.>E:?PVUK1K'39+&:Z6&^EF+GS1M##   ;I^!YR37-^.]!N+2?61IEHG]
MFP20W+QQCF!F4_.O^SG>"!P,CL.-96<G%F6"E:E"2=W)MOYIL]MHK!\&Z\/$
M?A>TORP,^WR[@#M(O!^F>OT(K>KE:L['KK4****0!1110 4444 %5M1OH=,T
MZXOIS^[@C+MSR<=A[GI5FO._BEK#1VMMHL&XR7!$LJJ"25!PHQWRV?\ OFKA
M'FDD<^*K>QHN?7IZ]# \)Z_!IUQK&N7J-<:E<,L5M;Q_>GDD8DJH^H7GM^.#
M8-OJOACQ]HVOZS.CRZRS07:QKA("<*J9] -G/^R>O6K7@ZSL/#YN]7\2?9[.
M[M L,8=O]4"@8A1W<AAG'/4#K6=XR\1S^.M)GM=#T6>;3[(FXDOY1M V YVC
MZ=LY.>@K>6L]-CGP5-T\.HRWU^^[/4]6UO3="M/M.IWD5M'VWGEO90.2?I7G
M&J:KJWQ$FMX_#ND&WMK6;S(M6N24:-A_<(^G(^;MD"K?@OPAIGB"PM_$NLW4
M^KWEP"=MR?DC()!7;DYP<]>,=A7I*(D4:QQHJ(H 55&  .P%8W4'IN=VLCS+
MP-X:TFXU&\.O)+=^);63_2([U]X _A= ?O @CDYQQC'&?3^@P*YSQ-H-Q>-#
MJ^D,L.MV0_<L>%F3O$_JI[>A]*N^'M>M_$&FBYC1H9XV,=S;/]^"0=5-*3YM
M06FAK4445!04444 9ZZ)I\-[<W]O;1PWMPA5YT'S<]_3/\^]97A#P_J.@PWB
MW^H_:S-(&106(7&<GGN<C/T[UTM%5S.UC'V%/G4TM5?\=PK,\2?\BOJ__7E-
M_P"@&M.LSQ)_R*^K_P#7E-_Z :2W-F?+-%%%=YRDMK;37MW#:VZ;YYY%CC3(
M&YB< <^YKIO^%;>+_P#H#/\ ]_H__BJR_"G_ ".&B?\ 7_!_Z,6OJ*L:E1Q>
MAI"*9\X_\*V\7_\ 0&?_ +_1_P#Q5'_"MO%__0&?_O\ 1_\ Q5?1U%9^WD5[
M-'SC_P *V\7_ /0&?_O]'_\ %4?\*V\7_P#0&?\ [_1__%5]'44>WD'LT?./
M_"MO%_\ T!G_ ._T?_Q5'_"MO%__ $!G_P"_T?\ \57T=11[>0>S1\X_\*V\
M7_\ 0&?_ +_1_P#Q5>E?"KPYJWAZ#5%U6S-L9FC,8+JV[ ;/0GU%>B44I57)
M68U!)W"L;Q=_R)NM_P#7C-_Z :V:QO%W_(FZW_UXS?\ H!K..Y3V/E^BBBN\
MYCTGX+_\C3??]>1_]#2O<*\/^"__ "--]_UY'_T-*]PKDK?$;T_A"OGKXJ_\
MC_>?]<XO_0!7T+7SU\5?^1_O/^N<7_H IT/B"IL<7111748'T'\*+2.V\!6L
MJ9W74LLKY/<,4_D@KMJY'X8MN^'FE^WFC_R*]==7#/XF=,=D%%%%2,**** "
MO /BW:+;>.9)5ZW-O'*WUY3_ -DKW^O"/C)('\9P*#REDBGZ[W/]:UH_$14V
M//:***ZS ^J- E,_AS2YB<F2TB8GZH#4'BO_ )$[6_\ KPG_ /1;5)X94IX4
MT=#U6QA!_P"^!4?BO_D3M;_Z\)__ $6U</VCIZ'R]1117<<QZ-\&%!\77;$
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M]S_JK98L?[[9_P#9/UKS"O6O@A_KM;_W8/\ V>JJ_ R8?$>OT445QG0%%%%
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M^\_ZYQ?^@"G0^(*FQQ=%%%=1@>S?!?6$DTV^T9V_>PR?:(P3U1@ 0!Z @?\
M?5>IU\L:!K=SX>UJWU.U.7B;YD)P'4]5/U'^-?2NAZ[8>(M+CU#3Y=\3\,IX
M:-NZL.Q'_P"KBN6M"SN;0E=6-*BBBL30**** "OF/QCK":[XMU'4(CNA>7;$
M1G!10%4\],@9_&O5/BAXVBTS3Y="L)0U_<+MG*_\L8SU!_VB.W8'/'%>'5TT
M86]YF5270*?%$\\T<4:EGD8*H'<G@4RNM^&VD'5_&]EE28;0_:I"#C&S[O\
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M55KIK20G 6Y7;_X]RH_$UB>)%-E\0/#7B*P'GP7;?89VAP5.[A22.O#$_P#
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MT!4CH0<<&M"LJD^9EQCRA1116904444 %%%% !1110 5C>+O^1-UO_KQF_\
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M.1U@9H@/P4@?I6ZKKJC-T^Q\WT5[JWP9\.,Q(N]44$]!+'@?^.4G_"F/#O\
MS^ZI_P!_8_\ XBJ]M$GV;/"Z "3@#)/05[]9_"/PM;9\Z.[N\_\ /><C'_?
M6NHTWPYHVCX.GZ9:V[@8WI&-_P#WUU_6DZ\>@U39X/H'PW\0ZZRN;4V5J3S-
M= IQQ]U?O'@\<8]Z]B\*^ M(\+*LL2?:;['-U*!N'&#M'\(Z^_/4UU-%8RJ2
MD:*"04445F4<WX__ .1#UC_KA_45\U5];30Q7$+0SQ)+$XPR.H93]0:H?\(]
MHG_0'T__ ,!D_P *UIU%%6(E#F9\L5ZU\$/]=K?^[!_[/7IO_"/:)_T!]/\
M_ 9/\*LVFG6-@7-G9V]OOQN\F)4W8Z9P.:J=52C:PHPL[EFBBBL#0**** "N
M1^)__).]5_[8_P#HU*ZZHKBW@NX&@N88YHFQNCD4,IP<\@^].+L[B:NCY+HK
MZG_X1[1/^@/I_P#X#)_A1_PCVB?] ?3_ /P&3_"NCVZ[&?LV>:? _P#YCO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%8WB4FYTF
MXTNVOK:WO[N,I"LT@!<'[P Z\C(X'>FE=V(J2Y(N1Q%B/^$X^(<EXWS:9I^-
MGHP!^4?\";+?0$5ZA6#X1\/#PYHBVKE&N9&,D[KT+=@/8#'ZUO5=22;LMD<V
M"HRIT^:?Q2U?^7R"BBBLSL"BBB@ K/N-%T^YU>UU62W'VZV!6.925.T@@@X^
M\.>AK0HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g34gh13buyut000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g34gh13buyut000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $& [L# 2(  A$! Q$!_\0
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M0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5!=6=K?1>5=VT,\?\ =E0,/R-3T4#3:=T<?J7PT\.W^YHH)+.0
M_P 5N^!_WR<C\L5QNJ?";5+;+Z;=0WB=D?\ =O\ KQ^HKV*BI<$ST:&;8NCM
M.Z\]?^"?-&H:3J&DR^5?V<UNW;S$(!^AZ'\*I5]0300W,+13Q)+&W#)(H8'Z
M@UQFL_##1-1W266_3YS_ ,\_FC)]U/\ 0BLW3?0]S#<0TY:5XV\UJO\ /\SQ
M*BNHUSP#KNB;I#;?:K8<^=;Y; ]QU'Y8]ZY>H::W/>HUZ=:/-3E=!1112-0H
MHHH N6>JZCIQ!LKZYM\=HI2H_(5T=C\2_$MG@/<Q72CM/$/YK@_K7(44TVC"
MKA:%7^)!/Y'JMA\7XSA=1TIU]7MY,_\ CK8_G73V'Q"\-7^ -0%NY_AN%*8_
M'[OZUX'15*HSS*V0X2?PWCZ/_.Y]/P7$%U$);>:.6,]&C8,#^(J6OF&WN[FS
ME\VUN)8)!_%$Y4_F*Z73_B-XEL,*;Q;I!_#<H&_48;]:M5%U/+K<.U5K2FGZ
MZ?YGO-%>9:?\7X6PNI:6Z>KV[AO_ !TX_G76:=XY\.:E@1:G%&Y_@G_=G_Q[
M@_@:I23/*K9;BJ/QP?RU_(Z&BD1UD0.C!E(R"#D&EJCA"BBB@ HHHH YCQ?>
M[(8;)#RYWO\ 0=/U_E7(5=U>\^W:I/.#E2VU/]T<"J5,05HZ%<_9=9MG)^5F
MV-]#Q6=0"0<@X(I@>K455TZZ%[IT%P#RZ#=]>A_6K52,**** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6=K6AV&OV#6E_"'0\JPX9#ZJ>QK1HH*A.4)*479H^??
M%7A"^\,7?[P&:R<_NKA1P?9O0_Y%<[7T]=VEO?VLEK=PI-!(,.CC(->)>-/
MUQX<E:[M=\VF,>'/+1$]F]O0UC*%M4?8Y7G"Q%J5;2?Y_P#!..HHHK,]X***
M* "BBB@ HHHH :Y^6HJ?(>@IE:QV/+Q4KU/0****9S!1110 4444 2H<C'I3
MJA4X:IJSDK,]7#5.>%GN@K1T/1KK7]6AT^T7YY#EGQPB]V/L/_K54M+2>_NX
MK6UB:6>5@J(O4FO>O!WA2'PQIFP[9+Z;!GE'K_='L/UHC&[.3,\PC@Z6GQ/9
M?J;&E:;;Z/IEO86B[885VCU)[D^Y.35RBBN@^"E)R;E+=A1110(**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ IDT,5Q"\,T:R12*5=&&0P/4&GT4 G;5'B7CGP*^@.=0T]6?36/S G)@)['
MU'H?P/OQ%?4,T,5Q"\,T:R12*5=&&0P/4&O#_'/@J3P[=?:[-6?3)6^4]3$W
M]T^WH?\ )QG"VJ/L,HS;VUJ%9^]T??\ X/YG'4445F?0A1110 4444 1/]XT
MV@\FBMD>+.7-)L****" HHHH **** "KEA:7&HW45I:1-+<2-M1%')-,LK&X
MU"X$-NFYNY[*/4UZKX"LK?0=16/ >2X7RWE(YSU 'H,T<O,85<RC@]M9/I_F
M=#X,\%P>&;;SY]DVI2+B24=$']U?;U/>NLHHJTK'R]>O4KU'4J.[84444S(*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***JZAJ-M
MIEM]HNG*1E@N0I//X4 6J*P&\9:,!D32-["(TQO&ND 9!G;V$= '145S#^.M
M,'W8;IO^ *!_.JTGCZW'^KL)6_WI O\ 0T =A1110 44C$*I8] ,FL+_ (3'
M1?\ GX?_ +]-_A0!O45SW_"::/\ WYO^_=1-XYTH#B.Z;Z(/\: .FHKDI/'M
MF/\ 5V<[?[Q _P :W=&U3^U]/%V(?*!<J%W;NGX4 :%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %0W=K!?6DMK<Q++!*NUT8<$5-5
M;4+^VTNQFO;R4101+N9C_+ZGTH*AS.2Y=SP?QCX4G\,:GL&Z2RF)-O*?3^Z?
M<?K7.5O^*_%%SXGU,SR9CM8\B"'^Z/4^Y[U@5S.U]#]'PGMO8Q]O\74****1
MT!2-PII:9)]VFMS.K+E@V1T445J>,%%%% !113HXWFD6.-&=V. JC)- -V&U
MK:3H-QJ;!SF*WSS(1U^E;&D^%E3;/J&&;J(0>!]?7Z5TP 50J@  8 ':K4>Y
MY&+S-1]RCJ^Y!9V5O80"&W0*HZGNQ]35E&9'5U.&4Y!]#2459X4I.3N]STZQ
MNEO+&&X7_EHH)'H>X_.K%<WX0NO,LYK5CS$VY?H?_KC]:Z2I **** "BBB@
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M0CN7)_[[-# VZ***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOU/?\*X&^O[G4KEKBZE+N>!Z >@'84[ +J.H3ZG>R75PV7;H.RCL!7<>!/\
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M1]Z7X?\ !/,)/A_9Z!IL,U_(+N^D<#:!^[0 <X'\7;K^5.' P*Z3QC/NOH(
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MD:=%&3&P^?'MCK7?44@/%:]2\++L\-60Y^ZQY]V)KC/%VF#3]7,D:[8;@;U
MZ!OXA_7\:[GP^NWP_8C_ *8@_G38&E7%Z_HVO:CJ,_E%GLR1Y:&8!>@[9]:[
M2BD!YG_PAVM?\^Z?]_5_QK+U#3KG3+G[/=($D*AL!@>/PKV"O.?''_(?7_K@
MO\S3$<W6GIV@ZAJENT]I$KQJ^PDN!S@'O]1697H7@3_D!S?]?+?^@K0!S?\
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M!@ 4M% !1110 4444 >>>.+18=7CN%&//CRW^\./Y8KF*[7X@?\ ,._[:?\
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M15"/9X?]1'_NC^5/ID/^HC_W1_*GU(PHHHH *BN+:&[A:&XB26,]589%2T4
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M^\=6T>5LK=YC_?<[5_+J?TI =5+*D$+RRL%C12S,>P%>/74YN;R:<]99&?\
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M96[*DEQD%V_A4=?QIFF:#::;AU'FS_\ /1QT^@[444 :E%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% $%S9VU[%Y=S!'*GHZYQ]/2L
M.X\$Z3,28Q/#[(^1^N:** *__"!V&>;JY_-?\*O6GA'2+5@Q@:=AWF;/Z=/T
MHHH W$18T"(H50, *, 4M%% $$MG;7$BR36\4CJ,*SH"1],U,J*B[44*H[ 8
MHHH 6F20Q3#$L:./1E!HHH 9!:V]KN^SP11;CEA&@7)_"IJ** ,FY\-:1=RO
M++:#S'8LS*[ DGJ>#6?)X&TI^4DN8_HX(_4444 1?\('8?\ /U<_^._X4^/P
M+IB\O-=/[;E _E110!H6_A;1[8@BS61O64EOT/%:R(D:!(T5%'15& *** '4
M444 %%%% !1110!@:CX1TR_D:55:WD/),70GZ?X8K-'@&#=S?R%?01C_ !HH
MH TK/P?I-HP9HWN&'_/9LC\AQ^=;RJJ*%50J@8  P!110 M%%% !1110 4V2
M-)4*2(KH>JL,@T44 8USX3T>Y);[,8F/>)BOZ=/TJ@? >GY^6ZN@/<J?Z444
M *G@33@<O<73>P91_2K]MX4T>V(/V7S6'>5BWZ=/THHH UXXHX8Q'%&L:#HJ
MC %/HHH *BGMH+J,1W$,<J YVR*&&?H:** &QV5I%_J[6%/]V,"IZ** "BBB
M@!KQI(,.BL/]H9JM)I>GR_ZRQMFSW,2_X444 6B 001D'K56/3+"+_5V-LG^
M[$H_I110!:550850H] ,4M%% !2$ C! (/8T44 026-I+_K+6!_]Z,&GP6T%
MK&8[>&.)"<[8U"C/T%%% $M%%% &9?>']+U!B\]HGF'JZ?*?TZ_C62_@33BV
M4N+E1Z;E/]*** %C\"Z:K9>>Y?VW #^5;5CHVGZ;S:VJ(W]\\M^9YHHH O44
M44 5X;"SM\>1:P1X_N1@58HHH *K3:?97'^NM()/]^,&BB@"S4-S:P7D#07$
M8DB;JIHHH QY?!VC2_=MWC_W)#_7-5&\":<3\EQ=+]64_P!*** &_P#"!V&>
M;JY_-?\ "K$7@G2(S\WGR_[\G^ %%% &K::-IUB0;>SB1AT;;EOS/-7J** "
&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>fgen-20190920.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-09-19T22:21:45.3620441+00:00 -->
<!-- Version            : 3.6.7150.26138 -->
<!-- Package ID         : 8c1eb636ad7746f58535fffa3334c209 -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:fgen="http://www.fibrogen.com/20190920" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.fibrogen.com/20190920" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" namespace="http://xbrl.sec.gov/country/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" namespace="http://xbrl.sec.gov/invest/2013-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" namespace="http://fasb.org/srt/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd" namespace="http://fasb.org/srt-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" namespace="http://fasb.org/srt-types/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" namespace="http://fasb.org/us-gaap/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" namespace="http://fasb.org/us-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" namespace="http://fasb.org/us-types/2019-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.fibrogen.com/20190920/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fgen-20190920_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fgen-20190920_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="fgen_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>fgen-20190920_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-09-19T22:21:45.3620441+00:00 -->
<!-- Version            : 3.6.7150.26138 -->
<!-- Package ID         : 8c1eb636ad7746f58535fffa3334c209 -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="fgen-20190920.xsd#fgen_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="fgen_DocumentAndEntityInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="fgen_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Document and entity information.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="fgen_DocumentAndEntityInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="fgen_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of each class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of each exchange on which registered</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>fgen-20190920_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2019-09-19T22:21:45.3620441+00:00 -->
<!-- Version            : 3.6.7150.26138 -->
<!-- Package ID         : 8c1eb636ad7746f58535fffa3334c209 -->
<!-- Copyright (c) 2019 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.fibrogen.com/20190920/role/TemplateLink" xlink:href="fgen-20190920.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="fgen-20190920.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="fgen-20190920.xsd#fgen_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="fgen_DocumentAndEntityInformationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fgen_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>9
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "fgen-8k_20190920.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "fgen-8k_20190920.htm"
     ]
    },
    "labelLink": {
     "local": [
      "fgen-20190920_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fgen-20190920_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "fgen-20190920.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 97,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "fgen",
   "nsuri": "http://www.fibrogen.com/20190920",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "fgen-8k_20190920.htm",
      "contextRef": "C_0000921299_20190920_20190920",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "fgen-8k_20190920.htm",
      "contextRef": "C_0000921299_20190920_20190920",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "fgen_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Document and entity information.",
        "label": "Document And Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.fibrogen.com/20190920",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>97</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="fgen-8k_20190920.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20190920/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="fgen-8k_20190920.htm">fgen-8k_20190920.htm</File>
    <File>fgen-20190920.xsd</File>
    <File>fgen-20190920_lab.xml</File>
    <File>fgen-20190920_pre.xml</File>
    <File>fgen-ex991_6.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>fgen-8k_20190920_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="fgen-20190920.xsd" xlink:type="simple"/>
    <context id="C_0000921299_20190920_20190920">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <startDate>2019-09-20</startDate>
            <endDate>2019-09-20</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0000921299_20190920_20190920" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="C_0000921299_20190920_20190920" id="F_000003">FIBROGEN INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="C_0000921299_20190920_20190920" id="F_000004">0000921299</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0000921299_20190920_20190920" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0000921299_20190920_20190920" id="F_000002">2019-09-20</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000921299_20190920_20190920" id="F_000007">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0000921299_20190920_20190920" id="F_000006">001-36740</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000921299_20190920_20190920" id="F_000008">77-0357827</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000921299_20190920_20190920" id="F_000009">409 Illinois Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0000921299_20190920_20190920" id="F_000010">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000921299_20190920_20190920" id="F_000011">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0000921299_20190920_20190920" id="F_000012">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000921299_20190920_20190920" id="F_000013">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000921299_20190920_20190920" id="F_000014">978-1200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0000921299_20190920_20190920" id="F_000015">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0000921299_20190920_20190920" id="F_000016">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0000921299_20190920_20190920" id="F_000017">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0000921299_20190920_20190920" id="F_000018">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="C_0000921299_20190920_20190920" id="F_000019">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000921299_20190920_20190920" id="F_000020">FGEN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000921299_20190920_20190920" id="F_000021">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000921299_20190920_20190920" id="F_000005">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6640825472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 20, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fgen_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 20,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">FIBROGEN INC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000921299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0357827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">409 Illinois Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">978-1200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FGEN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fgen_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fgen_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>16
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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ME+2S43IEEI9ZZYE,(XM,C&C3Q&O[_KV7,B%KD$OQ)\>1RJ5]J'7:M>' B.'
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M#?_)\@M02P$"% ,4    "  22#1/'R// \     3 @  "P
M@ $     7W)E;',O+G)E;'-02P$"% ,4    "  22#1/)^B'#H(   "Q
M$               @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M !)(-$\YW[CI[0   "L"   1              "  9D!  !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( !)(-$^97)PC$ 8  )PG   3
M  "  ;4"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ $D@T3YV2
M$;&A @  DPL  !@              ( !]@@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( !)(-$].Z>>!5P(  !L&   4
M  "  <T+  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( !)(-$^Z
MH3F*UP$  #(&   -              "  58.  !X;"]S='EL97,N>&UL4$L!
M A0#%     @ $D@T3Q9M(W]# 0  / (   \              ( !6!   'AL
M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( !)(-$__P"8(O0   (4"   :
M          "  <@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( !)(-$\+C]@#(0$  %<$   3              "  ;T2  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     *  H @ (   \4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001564590-19-035081-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-19-035081-xbrl.zip
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MH2KS=:Q+GBM5L#1HGW50%^<N7HL?_P-02P,$%     @ $D@T3^LC5NI>!P
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MD^KBZK-KG[J,3QD/']P, KEOZ[&97#\6/>95W%#M@#I$\D+HH_D\Q?H.A+R
M<1!S T5N2@&4RR.K**KA.2/YZ8JS52Y5^LKI&<[[GGIV[>/HDPG[+ 6Y((>D
M(P?T:,4C^4":T+ E8U>J6&GUC$T+.30C^@JCZWER!"+^=8<I<JH512; (<IG
M !ZM&&*2=\F%^G0: @_4F.6C*#VLE&I&IH)D92&5!.<'FK\G+Q_X,WNE>UE_
MO;L&M5=PQ[>]XE([)\5FF.4SDI)E^$VU#$Q MME#Z1]V2:_=Z^'VZX$_<O:"
MJ5OQ))&'H4'T#<SC6W]Y:D@H#?-_7J*RBB!3/%.3DET.43H>RJ1#>TT\,A%
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MO PR<+1D8 OW!Y1$Q&EV9>3G+;L^<G0T.4=YM5(I/5HV/,B=R7W6PFD.GW%
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MZ/TEO2#',S&C04MHZL.8(UH6OKK &K,!A\,>"&IUN69@:6-_2SB$*]%3PU2
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M -5A*$0T\UWT/.*HE<S!$MX=[<$QH.J!N5(ECN!N[+J;.]N;+US@J0EN";A
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MVB + _CP_U!+ 0(4 Q0    ( !)(-$^/C=4;+@4  &@8   1
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M4$L! A0#%     @ $D@T3V:+/#W:'0  M<L  !               ( !RR0
G &9G96XM97@Y.3%?-BYH=&U02P4&      4 !0!% 0  TT(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
